Ainos

Potential moat elements exist but are not yet durable.

Intangible assets include a patent portfolio and acquired medtech IP, plus a proprietary real‑world smell dataset that management says exceeded one billion records by September 2026. If large-scale deployments accrue, the dataset could evolve into a network/data-effect that improves model accuracy and creates switching costs.

However, scale, validation, and third‑party benchmarking are still limited publicly, and IP protection carries typical biotech and sensor-market uncertainties. Competitive entry by larger sensing and industrial AI vendors is plausible.

Net, we view: Intangibles 40/100 (patents, know-how, early Orphan Drug Designation signal but high enforcement risk); Switching costs 25/100 (industrial integrations are nascent); Network/data effects 35/100 (promising data flywheel but very early); Cost advantage 20/100 (no evidence yet); Efficient scale 20/100 (semiconductor niches are large and attractive but contested).

Weighting these factors yields a modest overall moat score pending real recurring usage and measurable ROI.

Management frames AI Nose as SmellTech‑as‑a‑Service with subscriptions, implying potential recurring revenue and value-based pricing if the platform demonstrably reduces scrap, downtime, or safety incidents in fabs.

The three‑year $2.1 million ASE order validates willingness to pay in a high‑value environment, and front‑end commercial orders could help expand use cases and referenceability. Still, the customer base is highly concentrated, deployments are early, and near-zero recognized revenue in H1 2026 suggests limited realized pricing power to date.

Biotech programs remain pre-commercial. Until the company shows gross margin expansion with scaled subscriptions and stickiness across multiple sites and customers, we score pricing power as latent but unproven.

Predictability is low. H1 2026 revenue was $313 with a net loss of $7.05 million, and the company continues to highlight future revenue opportunities in 2H 2026 rather than consistent organic growth. The industrial pipeline is promising but customer conversions, deployment pacing, and retention are unclear.

The therapeutics arm introduces regulatory, clinical, and timing risks despite Orphan Drug Designation for VELDONA in HIV-related oral warts. Geographic exposure is primarily Taiwan and Asia for semiconductor deployments, adding FX and geopolitical variables. We do not see a tollbooth-like revenue model in the data yet.

Balance sheet resilience is weak. As of June 30, 2026, cash and cash equivalents were $1.42 million against current liabilities of $16.28 million, including $11.0 million of convertible notes (reclassified as current), a $2.81 million related‑party loan, and $2.11 million of accrued expenses.

The 2025 10‑K explicitly states substantial doubt about the company’s ability to continue as a going concern. Trailing‑twelve‑month free cash flow through Q2 2026 is approximately −$4.5 million by our calculation: H2 2025 OCF (−$2.04 million) plus H1 2026 OCF (−$2.43 million), with minimal TTM capex (≈−$23 thousand).

The company remains dependent on equity and related‑party debt financing.

Capital allocation shows red flags for quality investors. The company relies on related‑party funding via convertible notes and a short‑term loan from ASE affiliates, issued at 6% compounded interest with conversion prices subject to anti‑dilution adjustments.

Share-based compensation and one‑time special stock bonuses were material in 2024–2025, and shares outstanding rose to 7.38 million by June 30, 2026 due to RSU deliveries, ATM issuance, and other grants.

While investments in platform R&D and channel partnerships may be strategically sensible, the combination of heavy dilution, thin cash cushion, and going‑concern disclosure indicates poor optionality for shareholders until profitable recurring revenue arrives.

The CEO (Eddy Tsai) and CFO (Christopher Lee) articulate a clear platform vision that integrates edge hardware, a real‑world smell dataset, and a smell language model, and have secured notable partnerships (ASE, Topco, Trusval) plus early orders in semiconductors and pilots in hospital settings.

That said, the record so far is heavy on announcements and light on recognized revenue, and financing choices have been dilutive and related‑party‑dependent. We see focus and persistence, but not yet an owner‑operator track record of capital discipline and compounding cash flows that we prize in this framework.